Answers are grounded in this paper and cite their sources.
Meta-analysis shows kidney function predicts cardiovascular efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes, suggesting biomarker-guided therapy.
Because decreased eGFR [significant] and albuminuria [trend] were found to predict a better efficacy for SGLT-2i in 3P-MACE reduction, this class of drug should be preferred in such patients. However, GLP-1RA may be considered for patients with normal eGFR because it showed better efficacy than SGLT-2i in this subgroup [trend].
No takes yet. Share an insight, caveat, or question.
Sohn et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: